baber/WOPTO huggingface dataset:
Patent NZ-513996-A (NZ)
Title: Cartridge for a liquid
Inventor: KLADDERS HEINRICH
IPC: B67D99/00
Filed: 2000-02-16
Abstract: A practically diffusion-tight cartridge which is capable of being stored over long periods of time and with which the liquid does not come into contact with the ambient air is required for withdrawing a liquid in a dosed manner out of the same over a duration of several months.  The cartridge is a container which is comprised of three shells consisting of a collapsible bag containing the liquid, a dimensionally stable container, and a stiff metal casing.  The cartridge can be detachably connected to a withdrawing device.  The cartridge can be provided with a micro-opening with which the time for the pressure compensation between the cartridge and the surroundings can be adjusted.  The cartridge is suited for aqueous and alcoholic liquids which contain a pharmacologically active ingredient.  The liquid in the cartridge is protected against external influences.  The cartridge can be used in an atomizer for generating an aerosol which can be inhaled for treating illnesses.
Patent NZ-519576-A (NZ)
Title: Method of suppressing oestrus, preventing pregnancy and improving carcass condition in a non-human animal by implanting a composition containing MGA and TBA
Inventor: MOSELEY WILLIAM M
IPC: A61K31/57
Filed: 2000-12-04
Abstract: An implant composition containing melengestrol acetate (MGA) and trenbolone acetate (TBA) that increases the growth performance, suppresses oestrus and prevents pregnancy in heifers. Preferably, the MGA and TBA can be provided in the same, separate or both separate and the same pellets.
Patent NZ-521786-A (NZ)
Title: NFIF-14b and NFIF-7a (nuclear factor kappa B inducing factor) polypeptides and nulciec acids and their use in compositions for inhibiting inflammation
Inventor: KAPLOW JUNE
IPC: A61K48/00
Filed: 2001-04-02
Abstract: A nucleic acid encodes a NFIF-7a (nuclear factor kB inducing factor) polypeptide comprising an amino acid sequence as shown in Figure 2 (SEQ ID NO:2). A pharmaceutical composition which lowers the expression or activity of NFIF an contain a nucleic acid antisense to the NFIF gene, a neutralizing antibody that binds to an NFIF polypeptide or a ribozyme that cuts RNA encoding an NFIF polypeptide. Also described are methods for evaluating whether a test compound is effective in inhibiting or enhancing the activity of NFIF-14b or NFIF-7a. An NFkB inducer can be used in the manufacture of a medicament for increasing expression of NFkB in a patient. A NFIF-14b or NFIF-7a inhibitor can be used in the manufacture of a medicament for inhibiting the expression of NFkB in a patient. Preferably the NFIF-14b or NFIF-7a inhibitor is used for inhibiting inflammation in a patient. An NFIF polypeptide or recombinant vector comprising the nucleic acid encoding an NFIF polypeptide, can be used for the treatment or prevention of an NFkB-regulated inflammatory response.
Patent NZ-521983-A (NZ)
Title: Journaling changes to system objects such as programs in the IBM OS/400 operating system
Inventor: TARBELL JAMES SCOTT
IPC: G06F11/14
Filed: 2002-10-14
Abstract: A system for journaling changes to system objects includes: i) a processor adapted to execute a dummy function in place of a system function wherein the dummy function executes the system function and generates copies of system objects resulting from system function execution for journaling; and ii) memory for use by the processor during execution.
Patent NZ-523752-A (NZ)
Title: Vanadium electrolyte preparation using asymmetric vanadium reduction cells and use of an asymmetric vanadium reduction cell for rebalancing the state of charge of the electrolytes of an operating vanadium redox battery
Inventor: PELLEGRI ALBERTO
IPC: H01M50/77
Filed: 2000-08-16
Abstract: A method of producing an acid vanadium electrolyte solution containing V+3 and V+4 in a desired concentration ratio from solid vanadium pentoxide fed into the electrolyte solution, is disclosed, wherein the method comprises electrochemically reducing at least partly of the dissolved vanadium in the acid electrolyte solution by circulating the electrolyte solution through a plurality of electrolytic cells in cascade to at least partly to a V+3 state; reacting the so reduced vanadium content in electrolyte solution outlet from the last of said electrolytic cells with a stoichiometric quantity of vanadium pentoxide obtaining an electrolyte solution containing vanadium substantially in a V+4; adding acid and water to maintain a certain molarity of the solution; and continuously recycling the electrolyte solution through the cascade of electrolytic cells while bleeding a stream of yielded electrolyte solution containing V+3 and V+4 in the desired concentrations at the exit of one of the cells of said cascade. Each cell is highly asymmetric, having a cathode and an anode with respective surface morphologies, geometry and mutual disposition such to establish on the anode surface a current density from 5 to 20 times greater than the current density on the projected cathode surface and evolve oxygen at the anode. An asymmetric cell of this type may be used in the circuit of one of the positive and negative electrolytes of a working battery for rebalancing the respective states of oxidation of their vanadium content.
Patent NZ-529422-A (NZ)
Title: Delivery of sedative-hypnotics through an inhalation route
Inventor: RABINOWITZ JOSHUA D
IPC: F24V30/00
Filed: 2002-05-17
Abstract: Disclosed is a composition for delivery of a sedative-hypnotic compound comprising: a condensation aerosol which is formed by volatilizing a sedative-hypnotic compound selected from the group consisting of zaleplon, zolpidem and zopiclone under conditions effective to produce a heated vapor of the compound and condensing the heated vapor of the compound to form condensation aerosol particles, wherein said condensation aerosol particles are characterized by less than 5% compound degradation products, and where the aerosol has an MMAD less than 5 micrometers.
Patent NZ-543183-A (NZ)
Title: Proximity sensor for level sensing
Inventor: ZIELINSKI MICHAEL R
IPC: G01F23/26
Filed: 2004-04-22
Abstract: Apparatus (20) for sensing the level of a substance in a tank is disclosed. First and second thin planar electrodes (12, 14) are located on a side wall portion (22) of the tank with one electrode vertically above the other. Each electrode is connected to a respective resistor and input of a detection circuit (16) and a strobe line is coupled to both resistors. The detection circuit provides a low-level output when the substance covers both or neither of the electrodes, and a high-level output when only one electrode is covered.
Patent NZ-549904-A (NZ)
Title: Thiadiazolidinones as GSK-3 inhibitors
Inventor: MARTINEZ GIL
IPC: A61K31/433
Filed: 2005-04-04
Abstract: Disclosed are thiadiazolidinone compounds of formula (I) wherein the substituents are as defined in the specification, which is are inhibitors of glycogen synthase kinase 3-beta (GSK-3), processes of preparation and its use for treating GSK-3 associated diseases such as Alzheimer's disease or non-insulin dependent diabetes mellitus.
Patent NZ-550208-A (NZ)
Title: An electronic gaming machine game and an electronic gaming method
Inventor: WILKINS PETER
Filed: 2006-09-29
Abstract: An electronically programmable machine includes an electronic display. The machine is programmed to produce a video image of a game including a first plurality of tokens. The tokens can represent balloons or dominoes. The machine is programmed to implement the steps of randomly or pseudo-random selecting a second plurality of tokens from within the first plurality of tokens. The second plurality of tokens is a subset of the first plurality of tokens selected on the basis of a characteristic of the tokens. The machine is programmed to cause the tokens to appear to fall. The characteristic can be a colour or a number. A winning result can be achieved when the pattern of the selected tokens matches one of one or more prize patterns. The tokens which are selected can be altered to provide a distinct visual appearance to distinguish them from the tokens which were not selected or can be removed from the display.
Patent NZ-551542-A (NZ)
Title: Piperazine derivatives of alkyl oxindoles
Inventor: BARKOCZY JOZSEF
IPC: A61K31/496
Filed: 2005-05-10
Abstract: Disclosed is a substituted 3-alkyl indol-2·one derivative of the general Formula (I), wherein R1 and R2 independently represent hydrogen, halogen, alkyl, alkoxy or trifluoromethyl; R3 represents hydrogen; R4 and R5 independently represent hydrogen, halogen, trifluoromethyl alkyl or alkoxy; m is an integer from 1-4, or a pharmaceutically acceptable acid addition salt thereof. Also disclosed is the use of a compound as defined above for the manufacture of a medicament suitable for the treatment or prophylaxis of central nervous disorders (such as depression, anxiety, compulsory disease, panic disease, social phobia, schizophrenia, mood disorders, mania, mental decline, stroke, cell death in certain parts of the central nervous system, neurodegeneration followed by mental decline, Alzheimer's disease, dementia, post-traumatic disease, or stress disease) or disorders of the cardiovascular system (such as hypertension).
Patent NZ-553839-A (NZ)
Title: A spring that separates into two parts, the parts clamp onto a support fabric held between them
Inventor: BOCK KLAUS
IPC: A47C27/06
Filed: 2006-02-21
Abstract: An upholstery spring device (1) is disclosed. The spring device (1) comprises a plurality of upholstery spring elements (2) which are joined to each other by means of a flexible connecting device (5) so as to form a joint unit. Each spring element (2) is made by the connection of two identical spring parts (3, 4) with the flexible connecting device (5) between them.
Patent NZ-556235-A (NZ)
Title: Methods of increasing seed yield using growth eIF-5A
Inventor: THOMPSON JOHN E
IPC: C07K14/415
Filed: 2005-12-05
Abstract: Disclosed is a method of increasing seed yield in a plant comprising incorporating into the genome of at least one cell of a plant a vector comprising a sense polynucleotide of growth eIF-5A and regulatory sequences operatively linked to the sense polynucleotide to provide transcription of said sense polynucleotide, and whereby said transcription of said sense polynucleotide increases expression of growth eIF-5A in a plant, and wherein the increased expression of growth eIF-5A increases seed yield in the plant and increases biomass of the plant as compared to wild type plants.
Patent NZ-583377-A (NZ)
Title: Method of eliciting an immune response against pandemic influenza virus
Inventor: ROCKMAN STEVE
IPC: A61K39/145
Filed: 2008-10-09
Abstract: 587377 Disclosed is the use of a composition comprising: At least one antigen of an endemic influenza subtype; and An antigen-free complex comprising saponin, a sterol, and a phospholipid (ISCOM) In the manufacture of a medicament for eliciting or inducing a protective immune response in a subject against a pandemic subtype of influenza virus.
Patent NZ-585238-A (NZ)
Title: A resealable opening for a can where the seal is pushed away from the can top inner surface to open
Inventor: RAMSEY CHRISTOPHER PAUL
IPC: B65D17/50
Filed: 2008-11-07
Abstract: Disclosed is a resealable can end combination that allows the contents to remain carbonated or pressurised. The combination comprises a metal can end and a resealable closure coupled to the can end, the can end comprising a peripheral wall and a centre panel, the centre panel including an upper surface, an opposing lower surface, and an aperture formed through the centre panel. The resealable closure comprises a base plate and a top plate coupled to the base plate at a first location, the closure has a sealed position in which at least one of the base plate and top plate contact the centre panel about the aperture to form a seal, an intermediate position in which the closure is proximate the aperture but not sealed, and a fully open position in which the aperture is exposed to enable pouring liquid through the aperture. The resealable closure also has a plug arrangement adapted to seal one or more vent pathways when the closure is in the sealed position, and a biasing means of a plastic spring adapted to bias the plug arrangement towards its sealed position. The base plate is downwardly moveable relative to the top plate when moved from the sealed position to the intermediate position. The base plate and top plate being translatable together relative to the can end from the intermediate position to the fully open position and translatable together relative to the can end back from the fully open position to the intermediate position. The base plate is upwardly moveable into engagement with the centre panel from the intermediate position into a resealed position forming at least one of a bore seal and a flange seal. The base plate further includes a wing, adapted to ride on a cam surface to allow relative movement between the base plate and the top plate to enable venting.
Patent NZ-585380-A (NZ)
Title: Thin film wound cover and suction assisted wound treatment system using the same
Inventor: BENTLEY LAUREN E
IPC: A61F13/02
Filed: 2008-10-09
Abstract: A composite structure 20 for a wound dressing comprises a cover 28, a stiffener 34, and a releasable liner 32. The cover 28 is a thin flexible film having an upper surface, an undersurface, a principal portion, a pair of marginal edges 28A, 28B and an adhesive on the undersurface. At least one marginal edge portion 28A, 28B and the principal portion of the cover 28 have the same flexibility. The stiffener 34 comprises a sheet having an upper surface, an undersurface, a principal portion and at least one marginal edge portion 34A, 34B. The stiffener 34 is disposed over and completely encompasses the cover 28. The undersurface of the principal portion of the stiffener 34 is releasably secured to the upper surface of the principal portion of the cover 28. At least one marginal edge portion 34A, 34B of the stiffener 34 is separated from the at least one marginal edge portion 28A, 28B of the cover 28 disposed below by a finger space.
Patent NZ-594728-A (NZ)
Title: Use of deferiprone for treatment and prevention of iron-related eye disorders
Inventor: SPINO MICHAEL
IPC: A61P27/02
Filed: 2009-11-12
Abstract: 594728 Disclosed is the use of deferiprone for the preparation of a medicament for the treatment or prevention of iron-related eye disorders, wherein the iron-related eye-disorder is selected from the group consisting of age-related macular degeneration, glaucoma, cataract, diabetic retinopathy, hereditary retinal degeneration, retinal detachment, ischemic retinopathy caused by retinal vein or artery occlusions, ischemic optic neuropathy, optic neuritis, and traumatic optic neuropathy. The medicaments are suitable for oral or topical administration.
Patent NZ-595367-A (NZ)
Title: A dose counting mechanism adapted to enclose a medicament delivery device
Inventor: SUTHERLAND GARTH CAMPBELL
IPC: G06M1/16
Filed: 2011-09-23
Abstract: Disclosed is a compliance monitor for monitoring patient usage of a medicament delivery device. The medicament delivery device has a store of medicament and medicament dispensing means. The compliance monitor includes a housing adapted to enclose the medicament delivery device, and a dose counter associated with the housing. The dose counter records the delivery of a dose of medicament to the patient from the medicament delivery device. The arrangement and construction of the housing allows the medicament delivery device to be loosely received within the housing and move relative to the housing during the delivery of a dose of medicament. This movement actuates the dose counter, either directly or indirectly, in order to record the delivery of the dose of medicament.
Patent NZ-595904-A (NZ)
Title: A novel formulation of meloxicam
Inventor: MEISER FELIX
IPC: A61K9/14
Filed: 2010-04-23
Abstract: The present disclosure relates to methods for producing particles of meloxicam using dry milling processes, wherein the average particle size, as determined on a particle number basis, or the median particle size, as determined on a particle volume basis, is equal to or less than 2000 nm. Also disclosed are compositions comprising meloxicam, medicaments produced using meloxicam in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of meloxicam administered by way of said medicaments.
Patent NZ-598711-A (NZ)
Title: Removable color gel basecoat for artificial nail coatings and methods therefore
Inventor: CONGER CHAD
IPC: A61Q3/02
Filed: 2010-08-30
Abstract: Disclosed is a polymerizable composition comprising: at least one reactive (meth)acrylate; at least one reactive urethane (meth)acrylate; at least one polymethylmethacrylate (PMMA) - polymethacrylic acid (PMAA) copolymer; at least one non-reactive, solvent-dissolvable polymer selected from the group consisting of cellulose esters, polyvinylbutyral resins, tosylamide (toluensulfonamide) formaldehyde resins, and mixtures thereof; and at least one non-reactive solvent selected from the group consisting of ketones, alkyl acetates, alcohols, alkanes, alkenes, and mixtures thereof; wherein upon exposure to actinic radiation, said polymerizable composition cures to an acrylic thermoset having voids defined therein. This composition is suitable for making artificial fingernail and toenail coatings which are removable.
Patent NZ-600902-A (NZ)
Title: Electronic apparatus and introducing method thereby
Inventor: OTA HIROSHI
IPC: G06F21/33
Filed: 2011-01-17
Abstract: 600902 Disclosed is an electronic apparatus capable of introducing an apparatus certificate of the electronic apparatus and an intermediate certificate of an intermediate certificate authority (4) which signs the apparatus certificate. The electronic apparatus includes a communication unit and a separation unit configured to separate the intermediate certificate and the apparatus certificate acquired by the communication unit from the intermediate certificate authority (4). An apparatus certificate verifying unit verifies a validity of the apparatus certificate separated by the separating unit and an intermediate certificate verifying unit verifies a validity of the intermediate certificate separated by the separating unit. An introducing unit introduces the apparatus certificate and the intermediate certificate only when both the apparatus certificate and the intermediate certificate are verified.
Patent NZ-601365-A (NZ)
Title: Method for the application of a conformal nanocoating by means of a low pressure plasma process
Inventor: MARTENS PETER
IPC: H05K3/28
Filed: 2011-01-21
Abstract: The invention relates to a conformal nanocoating applied by a low pressure plasma process. The invention also relates to a method for making such a conformal nanocoating on a three-dimensional nanostructure, in particular a three-dimensional structure containing electrically conductive and non-conductive elements such as an electronic device or PCB. The structure is degassed in a reaction chamber and then activated and/or cleaned prior to application of the coating by a plasma polymerisation process. The plasma is maintained by application of continuous RF (radio frequency) power across electrodes in the chamber.
Patent NZ-610701-A (NZ)
Title: Once daily formulation of lacosamide
Inventor: CAWELLO WILLI
IPC: A61P25/18
Filed: 2011-12-01
Abstract: Provided is a solid oral controlled release formulation of lacosamide wherein (a) an amount of about 8.5 wt-% to about 41 wt-% of lacosamide relative to the total lacosamide content of the formulation is released within 1 h, (b) an amount of about 15 wt-% to about 64 wt-% of lacosamide relative to the total lacosamide content of the formulation is released within 2 h, and/or 10 (c) an amount of about 28 wt-% to about 88 wt-% of lacosamide relative to the total lacosamide content of the formulation is released within 4 h, when the in-vitro release of lacosamide is measured according to USP (edition 24) method (711), dissolution apparatus 2, in 900 mL of 0.1 N HCI at 75 rpm. The formulation comprises a lacosamide release controlling agent either in the matrix of the formulation or as a release controlling layer. The formulation is suitable for once daily administration.
Patent NZ-620092-A (NZ)
Title: Arylsulfonamide ccr3 agtagonists
Inventor: LY TAI WEI
IPC: C07D295/26
Filed: 2010-04-21
Abstract: Disclosed are 4-(phenoxy)-3-(piperazin-1-ylsulfonyl)benzonitrile derivatives as represented by the general formula (I), wherein X is O or S; RYa is S(O)R1a, S(O)2R1a, S(O)NR1bR1c, or S(O)2NR1bR1c; and wherein the remaining substituents are as defined herein. Representative compounds include 4-(3,5-dimethylphenoxy)-3-(4-p-toluenesulphonylpiperazin-1-ylsulfonyl)benzonitrile, 3-(4-mesyl-piperazin-1-ylsulfonyl)-4-(3,5-dimethylphenoxy)benzonitrile, 4-(2,5-dichlorophenoxy)-3-(4-(dimethylaminosulphonyl)piperazin-1-ylsulfonyl)benzonitrile and 4-mesyl-1-([2-(2,5-dichloro-phenylthio)-5-nitro-phenyl]sulphonyl)-piperazine. Further disclosed is a pharmaceutical composition comprising a compound as defined above, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, or tautomer thereof; one or more pharmaceutically acceptable carriers or excipients; and optionally a second therapeutic agent; for the treatment, prevention, or amelioration of one or more symptoms of a CCR3-mediated disorder, disease, or condition in a subject, such as asthma, allergic asthma, exercise induced asthma, allergic rhinitis, perennial allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity, contact dermatitis, conjunctivitis, allergic conjunctivitis, eosinophilic bronchitis, food allergies, eosinophilic gastroenteritis, inflammatory bowel disease, ulcerative colitis, Crohn’s disease, mastocytosis, hyper IgE syndrome, systemic lupus erythematous, psoriasis, acne, multiple sclerosis, allograft rejection, reperfusion injury, chronic obstructive pulmonary disease, Churg-Strauss syndrome, sinusitis, basophilic leukemia, chronic urticaria, basophilic leukocytosis, psoriasis, eczema, COPD (chronic obstructive pulmonary disorder), arthritis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, and cardiovascular disorders.
Patent NZ-623907-A (NZ)
Title: Shockpad for artificial turf systems
Inventor: VAN VLIET ARIE HENDRIK FRANS
IPC: E01C13/08
Filed: 2012-10-22
Abstract: Disclosed is a three-dimensionally entangled elastomeric thermoplastic polymer extruded filament or fibre mat for a shockpad for an artificial turf system that provides improved shock absorption and/or energy restitution characteristics, especially over a prolonged period of time. The mat comprises a entangled mat of extruded filaments made from a thermoplastic elastomeric polyester, polyether or polyurethane polymer. A shockpad for artificial turf systems comprising a three-dimensional entangled mat of extruded filaments is also claimed. The shockpad also comprises one or more additional layers, each of the additional layers being a film, a layer of woven or nonwoven fibrous material, a two-dimensional grid or scrim, or a three-dimensional entangled mat of extruded filaments. An artificial turf system is also claimed, comprising a backing fabric, the backing fabric being tufted with at least one type of synthetic grass halms and coated to lock the tufted synthetic grass halms into place, and a shock absorbing layer of a shockpad with a three-dimensional entangled mat of extruded filaments.